AU2003299191A1 - Enteric composition for the manufacture of soft capsule wall - Google Patents

Enteric composition for the manufacture of soft capsule wall

Info

Publication number
AU2003299191A1
AU2003299191A1 AU2003299191A AU2003299191A AU2003299191A1 AU 2003299191 A1 AU2003299191 A1 AU 2003299191A1 AU 2003299191 A AU2003299191 A AU 2003299191A AU 2003299191 A AU2003299191 A AU 2003299191A AU 2003299191 A1 AU2003299191 A1 AU 2003299191A1
Authority
AU
Australia
Prior art keywords
manufacture
soft capsule
capsule wall
enteric composition
enteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003299191A
Other languages
English (en)
Inventor
Nachiappan Chidambaram
Aqeel A. Fatmi
Emadeldin M. Hassan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patheon Softgels Inc
Original Assignee
Banner Pharmacaps Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banner Pharmacaps Inc filed Critical Banner Pharmacaps Inc
Publication of AU2003299191A1 publication Critical patent/AU2003299191A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
AU2003299191A 2002-10-01 2003-06-27 Enteric composition for the manufacture of soft capsule wall Abandoned AU2003299191A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41518702P 2002-10-01 2002-10-01
US60/415,187 2002-10-01
PCT/US2003/020579 WO2004030658A1 (en) 2002-10-01 2003-06-27 Enteric composition for the manufacture of soft capsule wall

Publications (1)

Publication Number Publication Date
AU2003299191A1 true AU2003299191A1 (en) 2004-04-23

Family

ID=32069824

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299191A Abandoned AU2003299191A1 (en) 2002-10-01 2003-06-27 Enteric composition for the manufacture of soft capsule wall

Country Status (14)

Country Link
US (2) US8685445B2 (cg-RX-API-DMAC10.html)
EP (2) EP2772250B1 (cg-RX-API-DMAC10.html)
JP (1) JP5248739B2 (cg-RX-API-DMAC10.html)
CN (1) CN1688294A (cg-RX-API-DMAC10.html)
AU (1) AU2003299191A1 (cg-RX-API-DMAC10.html)
CA (1) CA2500663C (cg-RX-API-DMAC10.html)
CY (1) CY1118258T1 (cg-RX-API-DMAC10.html)
DK (2) DK1545475T3 (cg-RX-API-DMAC10.html)
ES (2) ES2500316T3 (cg-RX-API-DMAC10.html)
HU (1) HUE031650T2 (cg-RX-API-DMAC10.html)
MX (1) MXPA05003524A (cg-RX-API-DMAC10.html)
PT (2) PT2772250T (cg-RX-API-DMAC10.html)
SI (2) SI2772250T1 (cg-RX-API-DMAC10.html)
WO (1) WO2004030658A1 (cg-RX-API-DMAC10.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
JP5406530B2 (ja) 2005-10-26 2014-02-05 バナー ファーマキャプス， インコーポレイテッド 親水性ベヒクルに基づく二重制御された放出マトリクスシステム
CN101351196B (zh) 2005-10-26 2013-07-03 班纳制药公司 作为胶囊填充物的基于亲脂性载体的双重控释基质系统
US20070148248A1 (en) 2005-12-22 2007-06-28 Banner Pharmacaps, Inc. Gastric reflux resistant dosage forms
JP5183104B2 (ja) * 2006-06-19 2013-04-17 森下仁丹株式会社 口臭除去用多重ソフトカプセル
GB0706178D0 (en) * 2007-03-29 2007-05-09 Univ Aston Enteric pharmaceutical capsules
EP2219621B1 (en) 2007-11-12 2013-12-25 Pharmaceutics International, Inc. Tri-molecular complexes and their use in drug delivery systems
WO2009062356A1 (en) * 2007-11-13 2009-05-22 Shanghai Huiyuan Vegetal Capsule Co., Ltd Non-gelatin enteric hard capsule shell and preparation method thereof
WO2009136398A2 (en) 2008-05-06 2009-11-12 Dexcel Ltd Stable benzimidazole formulation
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
CN102307576A (zh) 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
US9011908B2 (en) 2009-04-06 2015-04-21 Banner Life Sciences Llc Progesterone solutions for increased bioavailability
EP2533770B1 (en) * 2010-02-12 2017-10-04 Sensient Colors LLC Enteric coating compositions and method of making the same
US9198868B2 (en) 2010-10-26 2015-12-01 Capsugel Belgium Nv Bulk enteric capsule shells
JP6397813B2 (ja) 2012-05-02 2018-09-26 キャプシュゲル・ベルジウム・エヌ・ヴィ ヒドロキシプロピルメチルセルロースアセテートスクシネート（ｈｐｍｃａｓ）の水性分散液
JP6389237B2 (ja) * 2013-03-15 2018-09-12 パセオン ソフトジェルズ インコーポレイティド 非ゼラチン性腸溶性軟質カプセル
BR112015006499A2 (pt) * 2013-04-23 2017-07-04 Zx Pharma Llc composição de óleo de horlelã-pimenta de liberação controlada microparticulada com revestimento entérico e métodos relacionados
US9504656B2 (en) 2013-10-21 2016-11-29 Banner Life Sciences, LLC Pharmaceutical compositions for poorly soluble active ingredients
ES2826201T3 (es) 2013-10-30 2021-05-17 Patheon Softgels Inc Cápsulas entéricas blandas que comprenden ácidos grasos poliinsaturados
EP3065720A1 (en) 2013-11-04 2016-09-14 Capsugel Belgium NV Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
CA2939990C (en) 2014-02-28 2018-07-10 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
WO2015157150A1 (en) * 2014-04-07 2015-10-15 Banner Life Sciences Llc Opioid abuse-deterrent controlled release formulations
US10772842B2 (en) 2015-01-09 2020-09-15 Patheon Softgels Inc. Abuse-deterrent opioids
WO2015195989A1 (en) * 2014-06-20 2015-12-23 Banner Life Sciences Llc Enteric soft capsule compositions
WO2015200149A1 (en) 2014-06-23 2015-12-30 Banner Life Sciences Llc All natural enteric soft capsules comprising active ingredients
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
WO2015200563A1 (en) * 2014-06-26 2015-12-30 Banner Life Sciences Llc Enhanced bioavailability of polysaturated fatty acids
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
MY184967A (en) 2014-10-06 2021-04-30 Fuji Capsule Co Ltd Method of producing enteric soft capsule
CA2960620C (en) 2014-10-06 2018-06-19 Fuji Capsule Co., Ltd. Method of manufacturing enteric seamless soft capsule
CA2962916C (en) * 2014-10-08 2021-06-15 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
WO2016161125A1 (en) * 2015-03-31 2016-10-06 University Of Vermont And State Agricultural College Methods for treating cryptosporidiosis using triazolopyridazines
US10182993B2 (en) 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
CN108697700B (zh) 2016-02-04 2021-08-17 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
PL239878B1 (pl) 2016-03-30 2022-01-24 Gdanski Univ Medyczny Wodna kompozycja oraz sposób wytwarzania dojelitowych elastycznych filmów do sporządzania kapsułek z wodnej kompozycji oraz dojelitowy elastyczny film do sporządzania kapsułek miękkich
NL2017219B1 (en) * 2016-07-22 2018-01-30 Rousselot B V Low cross-linking gelatine
AU2018231044B2 (en) 2017-03-08 2023-04-06 Cinrx Pharma, Llc Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
EP3768094B1 (en) 2018-03-15 2024-05-01 R.P. Scherer Technologies, LLC Enteric softgel capsules
CN108619523B (zh) * 2018-03-23 2020-06-30 浙江工业大学 一种可用于快速热塑包衣制剂的包衣膜片及其制备方法
WO2020144591A2 (en) * 2019-01-09 2020-07-16 Antony Benny Preparation of purified withanoside x from withania somnifera plant materials and its medicinal use for the treatment of health disorders
CN109566829A (zh) * 2019-02-11 2019-04-05 广东国方医药科技有限公司 牡丹籽油肠溶凝胶糖果及其制备方法
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
WO2020225395A1 (en) 2019-05-07 2020-11-12 Bausch Health Ireland Limited Liquid oral dosage formulations of methylnaltrexone
US20220249455A1 (en) * 2019-07-15 2022-08-11 R.P. Scherer Technologies, Llc Enteric proton pump inhibitor softgel capsule
WO2021050697A1 (en) * 2019-09-11 2021-03-18 Barlean's Organic Oils, Llc Softgel fill materials
EP4674410A3 (en) 2019-10-28 2026-03-18 R.P. Scherer Technologies, LLC Delayed release softgel capsules in higher ph environment
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
WO2021224138A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
CA3119012C (en) * 2021-05-18 2023-10-17 Gelentroceutics Inc. Formulation of intrinsically acid-resistant vegetarian-based and gelatin-based soft gel capsules for pharmaceutical/nutraceutical products
AU2023292098A1 (en) * 2022-06-13 2025-01-16 R.P. Scherer Technologies, Llc Enteric bisacodyl softgel capsule
US20250387338A1 (en) 2022-06-21 2025-12-25 Nutrition & Biosciences Usa 1, Llc Film forming delayed/enteric formulations for hard shell capsules, films and coatings
KR20260020112A (ko) * 2023-06-06 2026-02-10 알.피.쉐러 테크놀러지즈 엘엘씨 암브록솔 액체 제형
CN119112822A (zh) * 2024-09-05 2024-12-13 衡睿(珠海)生物科技有限公司 一种无包衣的肠溶软胶囊组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826666A (en) * 1972-07-20 1974-07-30 Parke Davis & Co Enteric capsules
DE2340060A1 (de) * 1973-08-08 1975-02-20 Scherer Gmbh R P Magensaftresistente gelatinekapseln und verfahren zu deren herstellung
US4138013A (en) * 1976-08-27 1979-02-06 Parke, Davis & Company Enteric capsules
US4790881A (en) * 1982-03-26 1988-12-13 Warner-Lambert Company Molded hydrophilic polymer
EG16027A (en) 1982-03-26 1986-12-30 Warner Lambert Co Hydrophilic polymer composition for injection molding
DE3222476A1 (de) 1982-06-15 1983-12-15 Warner-Lambert Co., 07950 Morris Plains, N.J. Magensaftresistente weichgelatinekapseln und verfahren zu ihrer herstellung
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4500453A (en) * 1984-06-29 1985-02-19 Dynagel Incorporated Cross-linked protein composition using aluminum salts of acetic acid
US4816259A (en) * 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
US5194464A (en) * 1988-09-27 1993-03-16 Takeda Chemical Industries, Ltd. Enteric film and preparatoin thereof
US5146730A (en) 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US6482516B1 (en) 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
US5330759A (en) 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
WO1998050019A1 (en) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6193999B1 (en) * 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
DE19922537A1 (de) * 1999-05-10 2000-11-16 Roland Bodmeier Darreichungsform zur Applikation in Körperöffnungen
DE60016617T2 (de) * 1999-10-01 2005-04-28 Natco Pharma Ltd., Banjara Hills Magensaftresistente gelartige weichkapsel
EP1184033A1 (en) * 2000-09-01 2002-03-06 Warner-Lambert Company Pectin film compositions
AU2003274683A1 (en) * 2002-08-02 2004-02-23 Scitech Centre NOVEL pH DEPENDENT ROBUST ENTERIC POLYMERIC CONTAINER, AN IMPROVEMENT OVER EXISTING ENTERIC DOSAGE FORMS.

Also Published As

Publication number Publication date
US20140348879A1 (en) 2014-11-27
ES2500316T3 (es) 2014-09-30
WO2004030658A1 (en) 2004-04-15
SI1545475T1 (sl) 2014-10-30
EP1545475B1 (en) 2014-07-16
JP5248739B2 (ja) 2013-07-31
US9433585B2 (en) 2016-09-06
CN1688294A (zh) 2005-10-26
CY1118258T1 (el) 2017-06-28
US20060165778A1 (en) 2006-07-27
SI2772250T1 (sl) 2017-03-31
HUE031650T2 (en) 2017-07-28
EP2772250B1 (en) 2016-09-28
ES2609059T3 (es) 2017-04-18
PT1545475E (pt) 2014-09-16
JP2006505542A (ja) 2006-02-16
DK2772250T3 (en) 2016-12-05
PT2772250T (pt) 2017-01-02
US8685445B2 (en) 2014-04-01
CA2500663A1 (en) 2004-04-15
CA2500663C (en) 2013-05-28
DK1545475T3 (da) 2014-07-28
EP2772250A1 (en) 2014-09-03
MXPA05003524A (es) 2005-10-04
EP1545475A1 (en) 2005-06-29

Similar Documents

Publication Publication Date Title
SI1545475T1 (sl) Enteričen sestavek za pripravo ovoja mehke kapsule
AU2003257550A1 (en) Soft capsule preparation
AU2002315779A1 (en) Soft capsules
AU2003218983A1 (en) Dynamic composition of restricted courses
AU2003280116A1 (en) Methods of making endoprostheses
IL163863A0 (en) Form of presentation for3-Ä(2-äÄ4-(hexyloxycarbonylamino-imino-methyl)-phenylaminoÜmethylü-1-methyl-1H-benzimidaz
AU2003231439A1 (en) Photostabilized soft capsule
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
AU2002367890A1 (en) Process for the preparation of 4-methyl-thiazole-5-carbaldehyde intermediate
AU2003265373A1 (en) Preparation of aztreonam
AU2003298725A1 (en) Preparation of metallotexaphyrins
AU2003901844A0 (en) The generation of images
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003243432A1 (en) Process of making phosphordiamidite compounds
AU2003293693A1 (en) Process for the preparation of bisphenols
AU2003240450A1 (en) Manufacture of ketopantolactone
AU2003255810A1 (en) Construction of lampshades
AU2002226616A8 (en) Preparation of pure 3-alkoxymethyl cephalosporins.
AU2003206318A1 (en) Blank for the preparation of denture parts
EP1386911A3 (de) Verfahren zur Herstellung von Acyloxybenzolsulfonaten
AU2003281197A1 (en) Liquid compositions for the oral administration of lorazepam
AU2003281158A1 (en) The treatment of emesis
EP1437347A3 (de) Verfahren zur herstellung von arylvinylhalogeniden und arylalkinen
PL356853A1 (en) Application of bacteriphages
AU2003226547A1 (en) Improved form of competition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase